Orion Group Holdings IncORNEarnings & Financial Report

NYSE · pharmaceutical industry

Orion Corporation, founded in 1917 and headquartered at Espoo, Finland, is a globally operating Finnish company which develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients for global markets. All of the company's manufacturing sites and the majority of its R&D units are in Finland.

Revenue

$225.1M

Gross Profit

$29.8M

Operating Profit

$5.3M

Net Profit

$3.3M

Gross Margin

13.2%

Operating Margin

2.4%

Net Margin

1.5%

YoY Growth

-0.7%

EPS

$0.08

Financial Flow

Orion Group Holdings Inc Q3 2025 Financial Summary

Orion Group Holdings Inc reported revenue of $225.1M for Q3 2025, with a net profit of $3.3M (1.5% margin). Cost of goods sold was $195.3M, operating expenses totaled $24.4M.

Key Financial Metrics

Total Revenue	$225.1M
Net Profit	$3.3M
Gross Margin	13.2%
Operating Margin	2.4%
Report Period	Q3 2025

Orion Group Holdings Inc Annual Revenue by Year

Orion Group Holdings Inc annual revenue history includes year-by-year totals (for example, 2024 revenue was $796.4M).

Year	Annual Revenue
2024	$796.4M
2023	$711.8M
2022	$748.3M

Income Statement

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Revenue	$201.6M	$160.7M	$192.2M	$226.7M	$216.9M	$188.7M	$205.3M	$225.1M
YoY Growth	2.8%	0.9%	5.3%	34.5%	7.6%	17.4%	6.8%	-0.7%

Balance Sheet

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Assets	$416.9M	$363.6M	$414.0M	$430.3M	$417.3M	$416.3M	$432.7M	$422.4M
Liabilities	$295.4M	$247.5M	$303.0M	$287.9M	$266.6M	$265.5M	$279.5M	$264.5M
Equity	$121.5M	$116.1M	$111.1M	$142.4M	$150.7M	$150.8M	$153.2M	$157.9M